Whole Eye Transplantation is No Longer Just Science Fiction

The technologies and techniques developed for eye transplantation and nerve regeneration may have significant translational potential for other biomedical needs including: spinal cord injury, central nervous system regeneration, retinal cell and tissue transplantation, and other forms of organ and tissue transplantation.  The post Whole Eye Transplantation is No Longer Just Science Fiction appeared first on…

Read More

Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt for Hot Inflammation Target

Gilead Sciences is acquiring LEO Pharma’s oral small molecule inhibitors of STAT6, a protein key to two validated inflammation pathways. Other STAT6 drug developers include Kymera Therapeutics and Sanofi-partnered Recludix Pharma, which is presenting this week during the J.P. Morgan Healthcare Conference. The post Gilead’s New $250M Drug R&D Pact Adds Contenders in the Hunt…

Read More